Home

personalized treatment
Personalized Treatment
Our Main Idea is to provide customised treatment options to each person. Many patients do not respond well to current therapies, therefore there is a need of personalized treatment.
 
Our tests will guide you and your health care providers in choosing the right treatment plan
RGCC
RGCC Group is a specialised medical genetics company and experts in developing, providing personalised cancer tests for patients and doctors. RGCC uses cutting-edge technology to design their tests which help to discover, analyse and screen cancer cells at every step of the disease.
Early detection
Different Cancers ONE test
Cancer can be developed in any possible organ of the human body. Any type of cancer, any stage of cancer, Multiple cancers with unknown primary origin. ONE stop diagnosis with a simple blood test.
 
We provide you with all the information you require for the best treatment options.
CTC’S & CSC’S
CTC’s & CSC’s
CTC’s and CSC’s can predict the treatment response and monitor the cancer progression. CTC’s and CSC’s can be used to search for specific biomarkers that can identify a tumour’s location, and predict potential metastases.
 
Our tests are designed in such way to understand the various aspects of cancer and helps the doctors in creating the accurate treatment plan
Early detection of Cancer/Relapse/Recurrence can “make a real difference..”
Pre-procedure counselling is offered to determine the benefits of CTC tests..
Best Quality tests for you

RGCC CAMBISEQ™

RGCC cancer analysis, mutational burden and instability sequencing (CAMBISeq) provides next- generation sequencing analysis on both DNA and RNA. RGCC CAMBISeq can help to identify variants in more than 500 genes,

See more >

aCGH Test

The array comparative genomic hybridisation (aCGH) test is used to identify abnormalities in a genome,when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer.

See more >

Metastat RGCC Test

Markers on CTCs that point out the potential organ for relapse. It can help practitioners in the prognosis of metastases trends in cancer patients.

See more >

Immune Frame Test

Profile of humoral and cellular immunity and cachexia. This test uses specific cellular markers and cytokine production to detect the type/types of cells that are responsible for activation / repression of the immune system of host.

See more >

Oncotrail RGCC Test

This test is a tailor made test for a specific type of malignancy such as breast cancer (Oncotrail for Breast), prostate (Oncotrail for Prostate), Colon, Melanoma, Lung, Sarcoma, Gastrointestinal for follow up control.

See more >

Oncotrace RGCC Test

This test will report the number of CTC's, any positive CSC's, and the immunophenotype of these cells.

See more >

Oncocount RGCC Test

This test will report only the number of Circulating Cancer Tumor Cells (CTC's). It does not include any other information concerning the CTC's or Circulating Cancer Stem Cells (CSC's) Immunophenotyping.

See more >

Onconomics Plus RGCC Test

4. This test is the combination of both Onconomics and Onconomics extracts test, which includes conventional treatment information, Gene profiling and the Integrative Treatment information.

See more >

Onconomics Extracts Test

This test includes only the assessment of natural substances and plant extracts for any anticancer potency. No chemotherapeutic agents tested and no tumor suppressor genes tested.

See more >

Onconomics RGCC Test

The test includes the chemosensitivity / chemoresistance assessment for cytotoxic drugs, monoclonal antibodies, and small molecules that inhibit specific targets eg.(TKI's) and Gene profiling at Epigenetic level. No Natural substances are tested.

See more >

VAXO-Q-Re

Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes and antibody producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).

See more >

ATA - Vaccine Prep from Tumour Cell Antigens

Autologous vaccines are created from a patient’s cancer cells, which are isolated from a blood sample. The cancer cells are cultured (effectively grown) in the laboratory, where they are combined with an immuno-stimulant designed to stimulate the body’s immune system into action. The disrupted cancer cells, now called tumour cell antigens, are re-administered into the patient through a vaccine. They provide the immune system with the blueprint to eliminate any remaining cancer cells in the body. The vaccine enables the body’s immune system to target and destroy cancer cells while leaving healthy tissue untouched.

See more >

DENDRITIC CELL THERAPY

DCs are exceptionally powerful initiators of immunity, with the ability to activate an immune response more potently than any other cell in the immune repertoire. Dendritic cells are a type of antigen presenting cells (APC) that play an important role in the adaptive immune system. They have the capacity to induce a primary immune response in the inactive or resting naïve T lymphocytes. To do this DCs capture antigens from invading bodies, which they process and present on their cell surface along with the necessary co-stimulation molecules. They also contribute to the function of B cells and help maintain their immune memory.

See more >

SUPPORTIVE OLIGONUCLEOTIDE THERAPY (SOT- Apoptosis Inducer)

SOT is a personalized therapy for cancer, viruses and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. During this therapy, we analyze a patient’s blood and create a complementary oligonucleotide sequence designed to interrupt the cells’ survival or growth. RGCC SOTs are available to RGCC Network doctors. Please contact us to discuss your requirements.

See more >
Information For Patients
We work with cancer patients to provide a range of personalised
tests so you can choose the best treatment.

7 Steps For RGCC Test

What Our Doctor's Say:

Dr IoannisPapasotiriou
Dr Ioannis Papasotiriou

Using this test helps oncologists take the possible drug out of chemo selection, increasing the likelihood of successful treatment, and reducing unnecessary toxic side effects by avoiding chemos that would not work

Every cancer patient is unique
Why choose our Tests?

CTC'S COUNT CAN BE CONSIDERED AS A PREDETERMINED PROGNOSTIC FACTOR , TO DETECT EARLY RELAPSE OR RECURRENCE CONDITIONS.

Upcoming Events

Find out more about our latest research, trials and education days

JUNE 2023

TRANSLATIONAL INTEGRATIVE MEDICINE IN CANCER CARE A 2-day interactive session on INTEGRATIVE ONCOLOGY was held at Hyderabad on 9th and…
Read More

FEB 2023

RGCC Oncology Medical Education and Training Sessions on Tests and Therapies A training session on RGCC TESTS and THERAPIES at…
Read More